Killing time for cancer cells (Q46555496)

23 December 2017

review article

1 reference

title

Killing time for cancer cells (English)

1 reference

23 December 2017

author name string

Shoshana Klein

series ordinal

1

1 reference

23 December 2017

Frank McCormick

series ordinal

2

1 reference

23 December 2017

Alexander Levitzki

series ordinal

3

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 July 2005

1 reference

23 December 2017

published in

Nature Reviews Cancer

1 reference

23 December 2017

volume

5

1 reference

23 December 2017

issue

7

1 reference

23 December 2017

page(s)

573-580

1 reference

23 December 2017

https://scigraph.springernature.com/pub.10.1038/nrc1651

exact match

0 references

cites work

ROS, stress-activated kinases and stress signaling in cancer

1 reference

Apoptosis and melanoma chemoresistance

21 January 2018

1 reference

B-RAF is a therapeutic target in melanoma

21 January 2018

1 reference

Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF.

21 January 2018

1 reference

The role of apoptosis in cancer development and treatment response

21 January 2018

1 reference

Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity

21 January 2018

1 reference

Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis

21 January 2018

1 reference

Reactivation of mutant p53: a new strategy for cancer therapy.

21 January 2018

1 reference

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

21 January 2018

1 reference

A recombinant adenovirus expressing wild-type Bax induces apoptosis in prostate cancer cells independently of their Bcl-2 status and androgen sensitivity

21 January 2018

1 reference

PI3K/Akt and apoptosis: size matters

21 January 2018

1 reference

Targeting the PI3K-Akt pathway in human cancer: rationale and promise

21 January 2018

1 reference

Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression

21 January 2018

1 reference

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

21 January 2018

1 reference

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway

21 January 2018

1 reference

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment.

21 January 2018

1 reference

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

21 January 2018

1 reference

Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase

21 January 2018

1 reference

Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases

21 January 2018

1 reference

Discontinuation of imatinib therapy after achieving a molecular response

21 January 2018

1 reference

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

21 January 2018

1 reference

Concepts of human leukemic development.

21 January 2018

1 reference

AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation

21 January 2018

1 reference

Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity

21 January 2018

1 reference

Prospective identification of tumorigenic breast cancer cells

21 January 2018

1 reference

Identification of human brain tumour initiating cells

21 January 2018

1 reference

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial

21 January 2018

1 reference

Preferential induction of apoptosis for primary human leukemic stem cells

21 January 2018

1 reference

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance

21 January 2018

1 reference

Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors

21 January 2018

1 reference

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

21 January 2018

1 reference

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

The case for early detection

21 January 2018

1 reference

A vision for the National Cancer Program in the United States.

21 January 2018

1 reference

Proteomic patterns for early cancer detection

21 January 2018

1 reference

Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors

21 January 2018

1 reference

Tyrosine kinase inhibition: an approach to drug development

31 March 2020

1 reference

Signal-transduction therapy. A novel approach to disease management

31 March 2020

1 reference

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

31 March 2020

1 reference

Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol

31 March 2020

1 reference

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

31 March 2020

1 reference

Mammalian target of rapamycin: a new molecular target for breast cancer

31 March 2020

1 reference

31 March 2020

Cell cycle and apoptosis

1 reference

Chronic myelogenous leukemia: mechanisms underlying disease progression.

31 March 2020

1 reference

Microarray and serial analysis of gene expression analyses identify known and novel transcripts overexpressed in hematopoietic stem cells.

31 March 2020

1 reference

Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors

31 March 2020

1 reference

RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class

31 March 2020

1 reference

Genomic profiling of viable and proliferative micrometastatic cells from early-stage breast cancer patients

31 March 2020

1 reference

Chemoprevention of colorectal cancer

31 March 2020

1 reference

Molecularly targeted approaches to the chemoprevention of lung cancer

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRC1651

1 reference

23 December 2017

PubMed ID

15965492

1 reference

23 December 2017